After years of waiting for a turnaround in its vaccines unit, it looks like Novartis may have sold it off at the right time. The Basel-based drugmaker Thursday reported stepped-up operating losses and flagging sales for the division, much of which will be on its way to former rival GlaxoSmithKline when the companies' $7.1 billion deal closes next year.
Personalized medicine is the latest trend in companion diagnostics, and companies are teaming up to develop comprehensive tests based on a patient's biologic characteristics. Roche's Ventana Medical Systems sees potential in the field, and recently inked a deal with Germany's Merck KGaA to develop a companion diagnostic test for different cancer indications.
Immunocore has struck another cancer R&D pact with one of the world's top drugmakers, signing a deal with Eli Lilly that'll both bring in short-term revenue and help the biotech build value in its proprietary pipeline.
Chinese clinical research outfit HD Biosciences has struck a deal with Marshall University to collaborate on cancer drug development, sharing costs and risks in hopes of commercializing new therapies.
The National Cancer Institute is terminating a $34 million mouse-model contract with Charles River Laboratories, possibly imperiling jobs at one of the CRO's Maryland outposts.
CRO inVentiv Health has agreed to share its expertise with the nonprofit Alliance for Clinical Research Excellence and Safety (ACRES), working to develop global standards for clinical trials.
Orthopedic specialist Smith & Nephew will market Blue Belt's surgical knee system in a worldwide agreement that could help breathe fresh life into Smith & Nephew's flagging knee implant revenue growth. The partnership with Smith & Nephew is the startup's first major distribution deal.
Soon, there will be a device to cure some forgetfulness if the Department of Defense's four-year grant of up to $40 million succeeds in fostering implants and electronic interfaces that diagnose and treat memory loss due to traumatic brain injury.
Germany's CureVac will implement its RNA stabilizing RNActive technology in its new collaboration with French firm Sanofi Pasteur to develop a messenger RNA-based vaccine targeting an undisclosed pathogen.
The pact focuses on identifying and selecting novel drug targets with the potential to become potent, selective therapeutics in the areas of oncology, inflammation and diabetes.